PROVIDENCE – Mnemosyne Pharmaceuticals Inc. closed today on an additional $6 million in Series A financing for its drug discovery efforts focused on the identification of new drug treatments for schizophrenia and other neuropsychiatric disorders. The new financing is from Atlas Venture, a Cambridge, Mass., early stage investment firm dedicated to financing disruptive innovation in…
Want More Free?
To access 2 more articles, please log in or register for free.
Registered users get access to a limited number of free articles every month.